The PI3K/Akt pathway is, therefore, at present being considered to be an attractive target for therapeutic intervention, and several compounds targeting the different components of the pathway have been developed or are in development (Vivanco and Sawyers, 2002; Luo et al, 2003; Hennessy et al, 2005; Guertin and Sabatini, 2007; Liu et al, 2009), with some of them currently in clinical trials for cancer treatment (Liu et al, 2009). Here, AKT1 is linked to cancer.